Company Overview and News

3
What's in Store for Cooper Companies' (COO) Q3 Earnings?

2018-08-20 zacks
The Cooper Companies’ (COO - Free Report) third-quarter fiscal 2018 results are scheduled to release on Aug 30, after market close.
DLTR COO VRX BURL NVS ROST

22
Tracking Jeffrey Ubben's ValueAct Portfolio - Q2 2018 Update

2018-08-20 seekingalpha - 1
The top three positions are Citigroup, Alliance Data Systems, and Twenty First Century Fox and they add up to ~41% of the portfolio.
SLMBP STX SLM VRX MS OSM EVA AES STRA ISM CBRE JSM AWI FOX C UFI SLMAP AFI CBG TRN ADS

28
Is Cocrystal Beating The Dead Hepatitis C Horse?

2018-08-14 seekingalpha
Cocrystal believes that there is still a suitable market for their ultra-short Hepatitis C regimen despite an industry-wide exodus out of Hepatitis C.
VRTX OPK GILD TEVA TEVVF BITRF VRX TEVJF TBPH SBPH ABBV PTCT COCP BMY ABBV

0
Twitter shares rise after short seller predicts big rally for the stock

2018-08-13 cnbc
"$TWTR has hit a level of relevancy as never before. With privacy concerns in its rear view & execution on all fronts -Citron expects new highs. Tgt price-$52," Left said on Twitter Monday.
VRX

51
Progenics Pharmaceuticals (Part II): Explicating The Ramifications Of The Azedra Approval

2018-08-13 seekingalpha - 2
Progenics is an intriguing bioscience approaching its “growth inflection.” As prognosticated, the company recently gained an FDA approval for its lead molecule, Azedra.
VRX SLXP PGNX BHC BHS

0
Bausch Health Cos.: Buy-And-Hold And Options Strategies

2018-08-09 seekingalpha
A robust debt reduction program, coupled with much needed organic growth, makes Bausch Health Companies a compelling investment prospect after earnings.
VRX BHS

0
Bausch Health posts $873-million (U.S.) loss linked to tax cost, asset impairments

2018-08-07 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
VRX

1
Bausch Health posts $873M US quarterly loss linked to tax cost, asset impairments

2018-08-07 cbc.ca - 1
Bausch Health Companies Inc. posted a net loss of $873 million US in the second quarter as the company formerly known as Valeant Pharmaceuticals experienced a bigger operating loss and a bigger provision for income taxes than last year.
VRX

3
CANADA STOCKS-TSX gains as energy shares get a boost from oil prices

2018-08-07 reuters
Aug 7 (Reuters) - Canada’s main stock index rose on Tuesday, as rising oil prices boosted shares of energy companies.
ENBBF IFSPF ACBFF PVG ENB SU ENB VRX ACB PVG EBBNF MAXR SU

0
CANADA STOCKS-Futures gain on higher oil prices

2018-08-07 reuters
Aug 7 (Reuters) - Futures pointed to a higher opening for Canada’s main stock index on Tuesday, as oil prices rose with renewed U.S. sanctions against Iran that are expected to tighten global crude supply.
VRX CTLR CLR

0
Bausch Health posts bigger quarterly loss on charge, tax provision

2018-08-07 reuters
Aug 7 (Reuters) - Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals, reported a bigger quarterly loss on Tuesday, due to an income tax provision and an asset impairment charge.
VRX

1
Salix, Cedars-Sinai Partner on Gut Microbiome–Related GI Treatments

2018-08-03 genengnews
Salix Pharmaceuticals will partner with Cedars-Sinai Medical Center to discover new treatments for gastrointestinal (GI) disorders related to conditions of the gut microbiome. [Source: © Sebastian Kaulitzki/Fotolia]
VRX SLXP

1
Salix, Cedars-Sinai Partner on Gut Microbiome-Related GI Treatments

2018-08-03 genengnews
Salix Pharmaceuticals will partner with Cedars-Sinai Medical Center to discover new treatments for gastrointestinal (GI) disorders related to conditions of the gut microbiome. [Source: © Sebastian Kaulitzki/Fotolia]
VRX SLXP

1
EyeGate Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update

2018-08-03 globenewswire - 1
WALTHAM, Mass., Aug. 03, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced financial results for the three month period ended June 30, 2018, and provided an update on recent corporate and operational activities.
EYEG VRX EYEGW

1
Amid EpiPen shortage, a Canadian-based company has approval for an alternative

2018-08-02 cbc.ca
As a worsening EpiPen shortage prompts questions about why Canada relies on just one pharmaceutical manufacturer to supply a life-saving treatment, a Laval, Que., drug company says it is "actively seeking" to bring another epinephrine self-injector that stops anaphylactic reactions to this country.
PFZ VRX 500680 PFE PFIZER

VRX: Valeant Pharmaceuticals International Stock Analysis and Research Report

2017-09-28 - Asif

Valeant Pharmaceuticals International, Inc. is a multinational, specialty pharmaceutical and medical device company that develops, manufactures, and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (“OTC”) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. We are diverse not only in our sources of revenue from our broad drug and medical device portfolio, but also among the therapeutic classes and geographies we serve. We generated revenues of $4,342 million and $4,792 million for the six months ended June 30, 2017 and 2016, respectively. Our portfolio of products falls into three reportable segments: (i) Bausch + Lomb/International, (ii) Branded Rx and (iii) U.S. Diversified Products. The Bausch + Lomb/International segment consists of: (i) sales in the U.S. of pharmaceutical products, OTC products a...

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...